NeuronBio is a biotechnology company located in Granada and Madrid, Spain that focuses on drug discovery and development, diagnostics tools, and bioservices. It has over 50 years of combined postdoctoral experience in R&D and has invested over €11 million in R&D. Its vision is to be an international reference in medical biotechnology within the next five years. It has a team of 55 employees and utilizes over 50 technologies for its screening and preclinical platforms.

1. 1

2. 2
Dr. Juan Mª Alfaro Commercial Manager
jmalfaro@neuronbio.com
@juanm_alfaro

3. 3
Overview
COMPANY PROFILE: Quoted on the Spanish Alternative Stock Market (MAB) LOCATIONS:
•Granada Health-Science Technology Park (headquarters)
•Madrid Science Park (laboratory, animal facilities & offices) BUSINESS LINES:
•Drug Discovery&Development
•Development of diagnostics tools
•R&D bioservices MANAGEMENT:
•UNE166.002 (Standard Operating Procedure for R&D)
•SGE21 (Ethical and CSR Management System) R&D:
•More than 50 years of accumulated postdoctoral experience in R&D
•Participation in 15 scientific projects
•Property of a wide collection of molecules (new chemical entities and reprofiling drugs) and natural products (>20.000 microbial extracts and plants)
•Over €11 million so far invested in R&D

4. 4
Mission & Vision
Vision
To be recognized as an international reference in the medical biotechnology during the next five years
Mission Creation, development and management of biotechnological companies

5. 5
Strenghts
TEAM: 55 people on the staff (including the three subsidary companies), a Board of Directors with wide business experience and an internationally recognized scientific advisory board TECHNOLOGY: Exclusive Drug Discovery & Development Platform consisting in: • A Screening Platform to identify potential neuroprotective candidates (high-throughput technologies) • A Preclinical Platform to select the better in vivo candidate and perform its development and optimization • More than 50 different technologies including in silico, in vitro and cellular assays as well as animal models • Efficacy, safety and pharmacokinetics MARKETS: Global Central Nervous System (CNS) market: $71 billion in 2010
•Neurodegenerative disorders market: >$21 billion in 2009
•Alzheimer’s disease (AD): $8 billion in 2009 and $9.6 billion in 2014 (expected)
•Drugs against AD: >$4.2 billion in 2012
•Diagnostic tools against AD: $1.2 billion in 2009 and $2.9 billion in 2014 (expected) Global R&D services market: $85-105 billion in 2013
•Non-clinical research market: $11-15 billion in 2013

6. 6
Holding structure
Mission: Discovery of neuroprotectants
Mission: Development of diagnostic tools
Mission: Development of bioprocesses
Mission:
1.Creation, development and management of biotech companies
2.R&D Services

7. 7
 Modelización in silico de docking y modelos QSAR
 Metabolómica y Proteómica
 Secuenciación masiva (transcriptoma completo)
 Modelos de cocultivo de modelización de paso de barrera intestinal y hematoencefálica
 Modelos de cultivos en 3D
 Modelos de enfermedad neurodegenerativa con células IPs y hESC
 Formulación galénica
 Servicios de técnicas de imagen (PET, MRN…)
 Servicios de caracterización de principios activos (físico-químico, estabilidad…)
 Servicios de análisis y cuantificación de moléculas en diversos tipos de matrices incluidas muestras biológicas para estudios farmacocinéticos
 Servicios de elaboración de dietas para animales
 Servicios de preclínica regulatoria
 Servicios de criopreservación
 Unidades de Fase I
PROYECTOS NEPSIA THERAPEUTICS

8. 8
MDC: Búsqueda de biomarcadores discriminatorios del deterioro cognitivo leve
Identificación de pacientes > 65 años:
Controles sanos, DCL y EA
Test neuropsicológicos
Historial médico
Criterios de inclusión/exclusión predeterminados
Extracción de muestras de fluidos periféricos:
Sangre total, suero y saliva
Ocasionalmente LCR para validación de biomarcadores
Gestión de muestras a través de Biobanco de Andalucía y FIBAO
Grupos de metabolómica para análisis de muestras SLOS: Búsqueda de biomarcadores del síndrome de Smith-Lemli-Opitz
Identificación de pacientes diagnosticados
Recogida de muestra inicial y/o de seguimiento
Gestión de muestras a través de FIBAO
PROYECTOS NEEXEN

9. 9
Contact
www.neuronbio.com www.neuronbioservices.com
Avda. Innovación nº1 Granada 181016 (Spain) Tel. [+34] 958 750 598 jmalfaro@neuronbio.com